FY2025 Earnings Estimate for SAGE Issued By Leerink Partnrs

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Research analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for Sage Therapeutics in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will earn ($3.05) per share for the year, down from their prior forecast of ($2.95). The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.46) per share. Leerink Partnrs also issued estimates for Sage Therapeutics’ FY2026 earnings at ($1.30) EPS, FY2027 earnings at ($1.64) EPS and FY2028 earnings at ($1.40) EPS.

Several other research analysts also recently commented on SAGE. Bank of America dropped their price objective on shares of Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating for the company in a report on Wednesday, October 9th. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, November 20th. Wedbush decreased their price objective on Sage Therapeutics from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Wednesday, October 9th. HC Wainwright restated a “neutral” rating and issued a $14.00 price target on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Finally, TD Cowen lowered their price objective on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Thursday, November 21st. Three equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.53.

Sage Therapeutics Stock Performance

Shares of NASDAQ:SAGE opened at $7.35 on Friday. The firm has a fifty day moving average price of $6.03 and a 200 day moving average price of $7.25. Sage Therapeutics has a fifty-two week low of $4.62 and a fifty-two week high of $27.39.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The company had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $10.80 million. During the same period last year, the business earned ($2.81) earnings per share. The company’s quarterly revenue was up 337.1% compared to the same quarter last year.

Institutional Investors Weigh In On Sage Therapeutics

Several large investors have recently modified their holdings of SAGE. China Universal Asset Management Co. Ltd. increased its holdings in shares of Sage Therapeutics by 66.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 4,672 shares during the period. Creative Planning purchased a new stake in shares of Sage Therapeutics during the third quarter valued at about $88,000. Empowered Funds LLC bought a new stake in shares of Sage Therapeutics in the 4th quarter valued at about $91,000. SG Americas Securities LLC grew its position in shares of Sage Therapeutics by 57.7% in the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 8,228 shares during the last quarter. Finally, Quest Partners LLC grew its position in shares of Sage Therapeutics by 56.3% in the 3rd quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 6,618 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.